Topics

AstraZeneca joins Bristol-Myers' run at Merck in lung cancer

10:00 EDT 28 Oct 2019 | BioPharmaDive

Imfinzi plus chemotherapy kept patients from progressing as quickly as chemo alone in POSEIDON trial, along with a triple combination, but oncologists will need to see survival and safety data.

Original Article: AstraZeneca joins Bristol-Myers' run at Merck in lung cancer

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca joins Bristol-Myers' run at Merck in lung cancer"

Quick Search